New vaccine to prevent respiratory illness in adults over 60

Plain-English translation of NCT07762014 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated September 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This is a Phase 2 clinical trial testing rBCG-N-RSV, a new vaccine designed to protect against two diseases: tuberculosis and respiratory syncytial virus (RSV), a respiratory infection common in older adults. The medication is a modified version of the traditional BCG vaccine that has been engineered to fight both conditions. Researchers will compare how safe and effective this new treatment is compared to the standard BCG vaccine currently used.

Respiratory syncytial virus can cause serious lung infections in older adults, and there is currently no vaccine available to prevent it. This trial aims to develop a single vaccine that protects against both tuberculosis and RSV, which could make prevention easier and more effective for seniors.

Do you qualify?

You likely qualify if…

you are at least 60 years old
you are in generally stable health or have well-controlled chronic conditions
you have not received a BCG vaccine in the past 10 years
you are willing to stay in your current city for the next 6 months and be contacted by the research team
you are able to commit to the study procedures and avoid other research studies during the trial period

You likely don't qualify if…

you have a fever within 24 hours of enrollment
you have a history of tuberculosis or active tuberculosis infection
you are taking immunosuppressive medications (drugs that weaken your immune system)
you have serious lung, heart, liver, or neurological conditions that could be worsened by the vaccine
you have uncontrolled high blood pressure or are currently being treated for cancer

What participation looks like

If you qualify, you will receive one injection of either the new vaccine or the standard BCG vaccine under the skin. The study involves a single vaccination day, though you will be asked to return for follow-up visits so researchers can monitor your safety and measure how well your immune system responds to the treatment over the following months. You will need to avoid other vaccines and elective surgeries during the study period and be available for the research team to contact you with results.

AI-generated summary from trial data · Sep 18, 2026 · Not medical advice

Trial locations(1 site)

Greece

Sotiria Thoracic Diseases Hospital of Athens, Athens